<?xml version="1.0" encoding="UTF-8"?>
<p>Therefore, do the benefits outweigh the risks? A joint statement issued on 17 March 2020 found that no experimental or clinical evidence demonstrating beneficial or adverse outcomes in COVID-19 patients using ACE inhibitors or ARB was available and that urgent additional research is needed. It stated that treatment should not be discontinued if patients become infected with SARS-CoV-2.
 <sup>
  <xref rid="bibr60-0004563220928361" ref-type="bibr">60</xref>
 </sup>
</p>
